To fully determine the utility of our novel rAAV model system, we will need to further establish the effects of mutant ubiquilin-2 expression in mouse brain and spinal cord beyond 6 months to determine whether we can induce pathological and phenotypic changes, such as paresis, expected for ALS/ALS-FTD. The gene discussed is UBQLN2; the disease is amyotrophic lateral sclerosis.